Table 3.

Adverse reactions in multiple myeloma patients treated with daratumumab monotherapy (16 mg/kg)[22]

System organ class	Adverse reaction	Frequency (all grades)	Incidence (%)
			All grades	Grades 3-4
Infections and infestations	Upper respiratory tract infection Nasopharyngitis Pneumonia†	Very common	17 12 10	1* 0 6*
Blood and lymphatic system disorders	Anemia Neutropenia Thrombocytopenia	Very common	25 22 20	17* 12 14
Metabolism and nutrition disorders	Decreased appetite	Very common	15	1*
Respiratory, thoracic, and mediastinal disorders	Cough	Very common	14	0
Gastrointestinal disorders	Nausea Diarrhea Constipation	Very common	21 15 14	0 0 0
Musculoskeletal and connective tissue disorders	Back pain Arthralgia Pain in extremity Musculoskeletal chest pain	Very common	20 16 15 10	2* 0 1* 1*
General disorders and administration site conditions	Fatigue Pyrexia	Very common	37 17	2* 1*
Injury, poisoning, and procedural complications	Infusion-related reaction‡	Very common	51	4*

*No Grade 4, ^†Pneumonia also includes the terms pneumonia streptococcal and lobar pneumonia, ^‡Infusion-related reactions include, but are not limited to, the following multiple adverse reaction terms: Nasal congestion, cough, chills, allergic rhinitis, throat irritation, dyspnea, nausea (all≥5%), bronchospasm (2.6%), hypertension (1.9%), and hypoxia (1.3%)